11/14/2025
Our Lafayette, CO, Pittsburgh, PA, and Tacoma, WA, hospitals are participating in a new clinical study to evaluate the efficacy of K9-ACV (autologous cancer vaccine) for the treatment of appendicular osteosarcoma (OSA) in dogs. Autologous cancer vaccines are produced from a dog's tumor and are therefore specialized to each individual patient.
Dogs older than one year of age and weighing more than 44 lbs. with a diagnosis of osteosarcoma may be eligible to participate.
https://bluepearlvet.com/clinical-studies/canine-osteosarcoma/
BluePearl is participating in a new clinical study to evaluate the efficacy of K9-ACV for the treatment of appendicular osteosarcoma (OSA) in dogs.